Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service LAA occlusion & loop recorders cases in Texas: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 138 | 5,388 | 44% |
| 2020 | 118 | 4,778 | 47% |
| 2021 | 151 | 6,132 | 51% |
| 2022 | 182 | 7,579 | 54% |
| 2023 | 207 | 8,798 | 57% |
| 2024 | 217 | 9,542 | 59% |
| 2025 from claims | – | 11,121 10,206–11,766 | 59% |
| 2026 forecast | – | 12,263 10,789–14,151 | 60% |
| 2027 forecast | – | 13,511 11,550–16,101 | 60% |
| 2028 forecast | – | 14,884 12,420–18,226 | 61% |
| 2029 forecast | – | 16,395 13,391–20,561 | 61% |
| 2030 forecast | – | 18,056 14,466–23,139 | 62% |
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 13% of the cases CMS names in Texas; 124 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 64% inpatient hospital, 19% hospital outpatient, 7% surgery center, 11% office. The share outside the hospital has moved −3 pts since 2019.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center | Office |
|---|---|---|---|---|
| 2026 · ~12,300 | ~8,000 | ~2,100 | ~940 | ~1,200 |
| 2027 · ~13,500 | ~8,900 | ~2,300 | ~1,100 | ~1,300 |
| 2028 · ~14,900 | ~9,900 | ~2,500 | ~1,200 | ~1,400 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 66% (64% in 2025), hospital outpatient about 17% (19% in 2025), office about 9% (11% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 310 | 13,955+10%/yr | +10%/yr | 5.3 | 38% | 26,400 in 2030+11%/yr |
| South Carolina | 71 | 3,614+14%/yr | +14%/yr | 4.7 | 11% | 6,460 in 2030+10%/yr |
| Virginia | 85 | 3,380+18%/yr | +18%/yr | 2.9 | 19% | 6,100 in 2030+10%/yr |
| Tennessee | 70 | 2,864+9.6%/yr | +9.6%/yr | 3.5 | 3% | 5,150 in 2030+10%/yr |
| Georgia | 70 | 2,787+8.8%/yr | +8.8%/yr | 2.8 | 7% | 5,510 in 2030+12%/yr |
| North Carolina | 76 | 2,760+8.6%/yr | +8.6%/yr | 2.4 | 7% | 4,660 in 2030+9.1%/yr |
| Oklahoma | 50 | 1,926+8.2%/yr | +8.2%/yr | 3.6 | 8% | 3,560 in 2030+11%/yr |
| Maryland | 56 | 1,696+8.1%/yr | +8.1%/yr | 1.8 | 35% | 3,080 in 2030+10%/yr |
| Mississippi | 37 | 1,533+9.3%/yr | +9.3%/yr | 3.6 | 28% | 2,480 in 2030+8.3%/yr |
| Alabama | 39 | 1,517+9.2%/yr | +9.2%/yr | 2.9 | 6% | 2,190 in 2030+6.3%/yr |
| Louisiana | 39 | 1,487+8.4%/yr | +8.4%/yr | 3.1 | 11% | 2,580 in 2030+9.6%/yr |
| Arkansas | 24 | 1,335+7.5%/yr | +7.5%/yr | 3.1 | 0% | 2,590 in 2030+12%/yr |
| Kentucky | 42 | 1,148+5.9%/yr | +5.9%/yr | 2.2 | 0% | 2,100 in 2030+11%/yr |
| West Virginia | 16 | 642+15%/yr | +15%/yr | 2.6 | 0% | 980 in 2030+7.4%/yr |
| Delaware | 17 | 625+4.5%/yr | +4.5%/yr | 3.3 | 31% | 810 in 2030+4.3%/yr |
| District of Columbia | 8 | 352+11%/yr | +11%/yr | 5.1 | 43% | 630 in 2030+10%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 220 | 11,944−3.2%/yr | −3.2%/yr | 5.81.0× | 7% | 12,500 in 2030+0.7%/yr |
| EP ablation | 177 | 10,931+7.5%/yr | +7.5%/yr | 4.21.2× | 0% | 20,900 in 2030+11%/yr |
LAA occlusion & loop recorders in every state, and its device makers · Every procedure market in Texas · Every state · Compare with Florida
Abbott leads with 52% of company spending on these surgeons in 2025, −4 pts on 2024.
In 2025, 5 companies reported engagement with Texas’s surgeons worth $729K in consulting, speaking, meals and travel tied to these products, about $3,361 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.